Paraza Pharma Strengthens Leadership with the Acquisition of Analytical Services from adMare BioInnovations to Catalyze Growth and Innovation
Montreal, QC – November 28, 2024 – Paraza Pharma, a leading contract research organization (CRO) specializing in end-to-end drug discovery services, is proud to announce the acquisition of adMare BioInnovations’ Analytical Services.
This strategic move within Technoparc Montreal, a renowned hub of innovation, further consolidates Paraza Pharma’s position as a premier drug discovery research organization. By integrating adMare Bioinnovations’ capabilities, Paraza Pharma enhances its ability to provide extended support to biotech and pharmaceutical sectors, by increasing its capabilities and capacity to meet the increasing demands of the industry.
Expanding Capacity to Support More Life Sciences Companies
The acquisition of adMare Bioinnovations’ Analytical Services by Paraza Pharma significantly increases its capacity to support its clients-partners. This move will strengthen Paraza Pharma’s already excellent reputation for delivering high-quality, reliable, and timely drug discovery support.
“We are excited to further enhance our capabilities, ensuring that Canada’s life sciences community continues to benefit from exceptional support and cutting-edge expertise,” said Arshad Siddiqui, President & CEO of Paraza Pharma. “By taking on adMare Bioinnovations’ Analytical Services, we are expanding our capacity to serve a wider range of companies in the rapidly evolving biotech and pharmaceutical sectors, helping them make data-driven decisions and accelerate their drug development programs.”
About Paraza Pharma
Paraza Pharma Inc. is a leading contract research organization (CRO) specializing in end-to-end drug discovery and development services. Dedicated to supporting biotech and pharmaceutical companies, startups, academic institutions, and venture capital firms, Paraza Pharma combines cutting-edge research capabilities with deep scientific expertise in Chemistry, Biology, and DMPK functions to deliver customized solutions that advance projects from concept to clinic. With a client-centric, seamless approach, Paraza Pharma provides innovative, high-quality services that position clients to accelerate the development of transformative therapies. For more information, please visit www.parazapharma.com.
For media inquiries, please contact:
Sultan Ahmad
Chief Business Officer
Paraza Pharma Inc.
sultan.ahmad@parazapharma.com
